The alpha-lipoic acid derivative DHLHZn

a new therapeutic agent for acute lung injury in vivo

Yoshiaki Shoji, Hiroya Takeuchi, Kazumasa Fukuda, Koichi Fukunaga, Rieko Nakamura, Tsunehiro Takahashi, Norihito Wada, Hirofumi Kawakubo, Taku Miyasho, Takahiro Hiratsuka, Masafumi Inomata, Tomoko Betsuyaku, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

Objective and design: An animal experiment was performed to demonstrate the anti-inflammatory effects of an alpha-lipoic acid (ALA) derivative, dihydrolipoyl histidinate zinc complex (DHLHZn) for acute lung injury (ALI) and to investigate the mechanism of action. Material: Rats were randomly divided into three experimental groups: control group (n = 17), DHLHZn(−) group (n = 11, ALI model rats), and DHLHZn(+) group (n = 12, ALI model rats treated by DHLHZn). Treatment: Lipopolysaccharides (LPS, 10 mg/kg) were administered intratracheally in the DHLHZn(−) group and the DHLHZn(+) group. For the DHLHZn(+) group, DHLHZn (100 mg/kg) was administered intraperitoneally 2 h prior to LPS administration. Methods: Four hours after LPS administration, bronchoalveolar lavage fluid (BALF) and lung tissue were collected. The findings were analyzed using the Mann–Whitney U test. Results: Total number of cells, number of neutrophils and lymphocytes, levels of various inflammatory cytokines, and NF-kB p65 concentration of BALF were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.05). ALI pathology scores were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.001). Conclusions: Anti-inflammatory effects of DHLHZn for ALI were demonstrated by BALF and histopathological findings. The mechanism of action of DHLHZn was considered to be via inhibition of the NF-kB signaling pathway. DHLHZn is thus suggested to be a new prophylactic agent for ALI.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalInflammation Research
DOIs
Publication statusAccepted/In press - 2017 Jun 1

Fingerprint

Thioctic Acid
Acute Lung Injury
Zinc
Therapeutics
Bronchoalveolar Lavage Fluid
NF-kappa B
Anti-Inflammatory Agents

Keywords

  • Acute lung injury
  • Alpha-lipoic acid
  • Dihydrolipoyl histidinate zinc complex
  • Nuclear factor-kappa B

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

The alpha-lipoic acid derivative DHLHZn : a new therapeutic agent for acute lung injury in vivo. / Shoji, Yoshiaki; Takeuchi, Hiroya; Fukuda, Kazumasa; Fukunaga, Koichi; Nakamura, Rieko; Takahashi, Tsunehiro; Wada, Norihito; Kawakubo, Hirofumi; Miyasho, Taku; Hiratsuka, Takahiro; Inomata, Masafumi; Betsuyaku, Tomoko; Kitagawa, Yuukou.

In: Inflammation Research, 01.06.2017, p. 1-9.

Research output: Contribution to journalArticle

Shoji, Yoshiaki ; Takeuchi, Hiroya ; Fukuda, Kazumasa ; Fukunaga, Koichi ; Nakamura, Rieko ; Takahashi, Tsunehiro ; Wada, Norihito ; Kawakubo, Hirofumi ; Miyasho, Taku ; Hiratsuka, Takahiro ; Inomata, Masafumi ; Betsuyaku, Tomoko ; Kitagawa, Yuukou. / The alpha-lipoic acid derivative DHLHZn : a new therapeutic agent for acute lung injury in vivo. In: Inflammation Research. 2017 ; pp. 1-9.
@article{03271821993c41cb95392e9311367bcf,
title = "The alpha-lipoic acid derivative DHLHZn: a new therapeutic agent for acute lung injury in vivo",
abstract = "Objective and design: An animal experiment was performed to demonstrate the anti-inflammatory effects of an alpha-lipoic acid (ALA) derivative, dihydrolipoyl histidinate zinc complex (DHLHZn) for acute lung injury (ALI) and to investigate the mechanism of action. Material: Rats were randomly divided into three experimental groups: control group (n = 17), DHLHZn(−) group (n = 11, ALI model rats), and DHLHZn(+) group (n = 12, ALI model rats treated by DHLHZn). Treatment: Lipopolysaccharides (LPS, 10 mg/kg) were administered intratracheally in the DHLHZn(−) group and the DHLHZn(+) group. For the DHLHZn(+) group, DHLHZn (100 mg/kg) was administered intraperitoneally 2 h prior to LPS administration. Methods: Four hours after LPS administration, bronchoalveolar lavage fluid (BALF) and lung tissue were collected. The findings were analyzed using the Mann–Whitney U test. Results: Total number of cells, number of neutrophils and lymphocytes, levels of various inflammatory cytokines, and NF-kB p65 concentration of BALF were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.05). ALI pathology scores were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.001). Conclusions: Anti-inflammatory effects of DHLHZn for ALI were demonstrated by BALF and histopathological findings. The mechanism of action of DHLHZn was considered to be via inhibition of the NF-kB signaling pathway. DHLHZn is thus suggested to be a new prophylactic agent for ALI.",
keywords = "Acute lung injury, Alpha-lipoic acid, Dihydrolipoyl histidinate zinc complex, Nuclear factor-kappa B",
author = "Yoshiaki Shoji and Hiroya Takeuchi and Kazumasa Fukuda and Koichi Fukunaga and Rieko Nakamura and Tsunehiro Takahashi and Norihito Wada and Hirofumi Kawakubo and Taku Miyasho and Takahiro Hiratsuka and Masafumi Inomata and Tomoko Betsuyaku and Yuukou Kitagawa",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s00011-017-1059-x",
language = "English",
pages = "1--9",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - The alpha-lipoic acid derivative DHLHZn

T2 - a new therapeutic agent for acute lung injury in vivo

AU - Shoji, Yoshiaki

AU - Takeuchi, Hiroya

AU - Fukuda, Kazumasa

AU - Fukunaga, Koichi

AU - Nakamura, Rieko

AU - Takahashi, Tsunehiro

AU - Wada, Norihito

AU - Kawakubo, Hirofumi

AU - Miyasho, Taku

AU - Hiratsuka, Takahiro

AU - Inomata, Masafumi

AU - Betsuyaku, Tomoko

AU - Kitagawa, Yuukou

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Objective and design: An animal experiment was performed to demonstrate the anti-inflammatory effects of an alpha-lipoic acid (ALA) derivative, dihydrolipoyl histidinate zinc complex (DHLHZn) for acute lung injury (ALI) and to investigate the mechanism of action. Material: Rats were randomly divided into three experimental groups: control group (n = 17), DHLHZn(−) group (n = 11, ALI model rats), and DHLHZn(+) group (n = 12, ALI model rats treated by DHLHZn). Treatment: Lipopolysaccharides (LPS, 10 mg/kg) were administered intratracheally in the DHLHZn(−) group and the DHLHZn(+) group. For the DHLHZn(+) group, DHLHZn (100 mg/kg) was administered intraperitoneally 2 h prior to LPS administration. Methods: Four hours after LPS administration, bronchoalveolar lavage fluid (BALF) and lung tissue were collected. The findings were analyzed using the Mann–Whitney U test. Results: Total number of cells, number of neutrophils and lymphocytes, levels of various inflammatory cytokines, and NF-kB p65 concentration of BALF were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.05). ALI pathology scores were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.001). Conclusions: Anti-inflammatory effects of DHLHZn for ALI were demonstrated by BALF and histopathological findings. The mechanism of action of DHLHZn was considered to be via inhibition of the NF-kB signaling pathway. DHLHZn is thus suggested to be a new prophylactic agent for ALI.

AB - Objective and design: An animal experiment was performed to demonstrate the anti-inflammatory effects of an alpha-lipoic acid (ALA) derivative, dihydrolipoyl histidinate zinc complex (DHLHZn) for acute lung injury (ALI) and to investigate the mechanism of action. Material: Rats were randomly divided into three experimental groups: control group (n = 17), DHLHZn(−) group (n = 11, ALI model rats), and DHLHZn(+) group (n = 12, ALI model rats treated by DHLHZn). Treatment: Lipopolysaccharides (LPS, 10 mg/kg) were administered intratracheally in the DHLHZn(−) group and the DHLHZn(+) group. For the DHLHZn(+) group, DHLHZn (100 mg/kg) was administered intraperitoneally 2 h prior to LPS administration. Methods: Four hours after LPS administration, bronchoalveolar lavage fluid (BALF) and lung tissue were collected. The findings were analyzed using the Mann–Whitney U test. Results: Total number of cells, number of neutrophils and lymphocytes, levels of various inflammatory cytokines, and NF-kB p65 concentration of BALF were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.05). ALI pathology scores were significantly lower in the DHLHZn(+) group than in the DHLHZn(−) group (p < 0.001). Conclusions: Anti-inflammatory effects of DHLHZn for ALI were demonstrated by BALF and histopathological findings. The mechanism of action of DHLHZn was considered to be via inhibition of the NF-kB signaling pathway. DHLHZn is thus suggested to be a new prophylactic agent for ALI.

KW - Acute lung injury

KW - Alpha-lipoic acid

KW - Dihydrolipoyl histidinate zinc complex

KW - Nuclear factor-kappa B

UR - http://www.scopus.com/inward/record.url?scp=85020061121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020061121&partnerID=8YFLogxK

U2 - 10.1007/s00011-017-1059-x

DO - 10.1007/s00011-017-1059-x

M3 - Article

SP - 1

EP - 9

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

ER -